Tenza

Tenza is an early-stage biotech leveraging synthetic biology to create a novel drug delivery platform. Its core technology involves genetically engineering probiotic bacteria to manufacture and deliver therapeutic peptides and proteins directly within the body, targeting metabolic diseases. The company is privately held, appears to be in a pre-clinical or platform optimization stage, and is led by a team with strong scientific and entrepreneurial credentials, including renowned geneticist George Church as a co-founder. Tenza's approach seeks to address key challenges in biologics delivery, including cost, patient compliance, and efficacy.

Genetic engineering of probiotic microbes to function as in vivo factories for the production and localized delivery of therapeutic peptides and proteins.

Tenza competes in the live biotherapeutic product (LBP) and novel drug delivery space, facing competition from other microbiome-focused biotechs (e.g., Seres Therapeutics, Vedanta Biosciences) and companies developing oral delivery technologies for peptides and proteins. Its differentiation lies in the specific engineering of probiotics as in vivo protein factories.